At first glance, the difference between cosmetic and a medical device can appear surprisingly small
Products may contain many of the same raw materials, be manufactured using comparable processes and even be presented in similar formats.
From a regulatory perspective, however, the distinction can be significant.
How a product is classified affects the regulatory framework that applies, the evidence required and the claims that can be made when it is placed on the market. Regulatory positioning should therefore be considered from the early stages of product development.
It’s Not Just the Ingredients That Define the Product
A common misconception is that medical devices are necessarily formulated using fundamentally different raw materials from cosmetics.
In practice, the same types of ingredients can appear across different product categories. Similar emollients, humectants, polymers, rheology modifiers, surfactants and preservatives may feature in both cosmetic and medical device formulations.
An ingredient list alone therefore rarely tells the full regulatory story. What matters is the finished product: what it is intended to do, how it achieves that effect and how it is presented.
For formulators, the practical consequence is important: a formulation cannot be considered independently of the purpose being developed around it.
Intended Purpose Shapes the Regulatory Pathway
Under the EU Cosmetics Regulation, cosmetic products are intended principally to clean or perfume external parts of the human body, change their appearance, protect them, keep them in good condition or correct body odours.
Medical devices, by contrast, have one or more of the specific medical purposes described within the Medical Device Regulation. Their principal intended action is not achieved by pharmacological, immunological or metabolic means, although their function may be assisted by such means.
This means apparently small development decisions can have significant consequences. Describing a product as helping to keep healthy skin in good condition, for example, creates a different regulatory proposition from positioning it for the management or treatment of an injury.
The formulation may not have changed, but its regulatory context has.
Similar Formulation, Different Regulatory Considerations
Consider two topical gels containing similar types of raw materials, such as a polymer, humectant, rheology modifier and preservative.
One is developed as a cosmetic gel intended to moisturise and soothe healthy skin. Another is intended for a specific medical purpose.
At formulation level, the products may look remarkably similar. Their regulatory pathways, however, can lead to different requirements for testing, technical documentation and supporting evidence.
This is why regulatory and formulation strategies should develop together. Leaving regulatory positioning until late in a project can expose a mismatch between the product being developed and the claims or evidence needed to bring it to market.
The Grey Areas: When Classification Becomes More Difficult
Some products sit close to regulatory boundaries. Wound care products, oral products, ophthalmic formulations and certain lubricants are examples where careful assessment may be needed.
A wound gel illustrates why.
Imagine a gel that forms a physical layer over a wound and helps maintain a moist environment. The ingredient list alone does not establish how the finished product should be classified. Its precise purpose and the way it achieves its claimed effect become critical to the assessment.
Change those characteristics and the regulatory position may change too. A product presented for use on healthy skin raises different considerations from one presented for the management of damaged tissue. If its principal intended action instead depends on pharmacological action, the potential relevance of medicines legislation (Directive 2001/83/EC) may also need to be considered.
Borderline classification is therefore rarely answered by asking, “Which category does this ingredient belong to?” A more useful question is, “What is this finished product intended to do, and how does it achieve that effect?”
Addressing that question early can identify potential classification issues before significant investment is made in formulation optimisation, testing and documentation.
Four Questions to Ask Early in Development
Rather than treating regulatory classification as a final compliance exercise, developers can use four questions during the early stages of a project:
1. What is the intended purpose of the finished product?
Define what the product is expected to do, for whom and under what conditions of use.
2. How does the product achieve its principal intended action?
Consider how the claimed effect is produced and what that could mean for classification.
3. Which regulatory framework is likely to apply?
Consider this while the formulation and positioning are still being developed, particularly for products close to a regulatory boundary.
4. What evidence will be needed to support safety and performance?
Identifying requirements early allows appropriate testing and documentation to be built into the development programme.
For formulators, product developers and raw material suppliers, that matters because products that look similar on the bench can require very different development strategies
Aligning regulatory and formulation thinking early helps ensure that the product, supporting evidence and intended market positioning are all being developed towards the same goal.
Regulatory classification depends on the specific characteristics, intended purpose and presentation of an individual product. The regulatory principles and examples discussed in this article should be reviewed against the applicable legislation and current regulatory guidance before being relied upon for a particular product.
Contact Us:
If you would like to learn more about medical devices, then please contact us on Pharma@Surfachem.com and our expert technical team can help you with your queries.
